Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of AZD9056 in Rheumatoid Arthritis
NCT00520572Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of AZD9056 in rheumatoid arthritis (RA) (6 arms), sponsored by AstraZeneca. Primary endpoint: American College of Rheumatology 20 Response at 6 months. Started Aug 2007; status: completed.
02
Drugs
AZD9056
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00520572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00520572.